Retatrutide and tesamorelin run on two different clocks, so there is no single answer to how long you run the stack. Retatrutide runs for the length of the fat loss phase, tesamorelin runs for months because the change it makes is slow, and the real question is not when to cycle off but what happens when you stop.
This page settles the three questions that come after the decision to stack retatrutide and tesamorelin has already been made: how long each one runs, whether either needs to be cycled off, and what dose ranges show up in the research. It is written for the researcher who already understands why these two get paired and now wants the timeline worked out, with the reasoning behind it and not a borrowed rule from another compound class.
How long can you run retatrutide and tesamorelin together
The honest answer is that "together" is the wrong frame for the timeline. For most people these two compounds do not start on the same day and they do not finish on the same day. Retatrutide usually comes first because it moves the scale. Tesamorelin comes in later, once weight is under control and what is left is deep abdominal fat and the job of holding on to muscle. That order is the reason the how long answer is different for each one, and it is laid out step by step in our breakdown of why retatrutide and tesamorelin sequencing matters more than stacking.
So the stack has three windows, not one. There is a stretch where retatrutide runs alone, a stretch where the two overlap, and a stretch where tesamorelin may keep running after retatrutide has done its job. How long the overlap lasts depends on how much fat there is left to lose when tesamorelin enters, not on a number on a calendar.
If the question in your head right now is when the overlap should start for your own situation, ask it here and the first answer shows in full for free.
How long to run retatrutide: tied to the fat loss phase
Retatrutide is a fat loss tool. It works on three receptors, GLP-1 and GIP which turn appetite down and help with blood sugar, plus glucagon which tells the body to burn stored energy rather than only eat less. Because its whole job is moving fat, the length of time it runs is tied to one thing, the fat loss phase.
In the published clinical trials, people stayed on retatrutide for roughly 24 to 48 weeks, with the larger phase 3 programs running longer. Those numbers describe how long the studies lasted. They are not a built in limit on the compound, and they are not a target to hit. Based on the data, the more useful way to think about it is that retatrutide runs for as long as losing fat is still the job. When fat stops being the main problem, that phase is over, and so is most of the reason to keep it running.
That also explains why the scale tends to slow down later in a run. As body weight drops, the body spends less energy and the gap between intake and output narrows. A slowing scale late in the phase is often a sign the phase is ending, not that the compound broke, which is covered in more detail in the free Reta, Tesa, and CJC sequencing guide.
How long to run tesamorelin: the slow visceral fat clock
Tesamorelin is on a completely different clock, and it is a slow one. It is a GHRH analog, which means it mimics the signal your brain sends to tell the pituitary gland to release a pulse of growth hormone. That growth hormone pulse is what research links to the drop in visceral fat, the deep fat packed around the organs.
Visceral fat does not move quickly. The trials that got tesamorelin approved measured results at 26 weeks, and the change in visceral fat was measured on scans, not on a bathroom scale. Research suggests you are looking at months before a real change can even be measured. Someone who runs tesamorelin for four weeks, sees nothing, and quits never gave it the time it needs to show anything. That is not the compound failing. That is the clock.
Put the two side by side and the timeline looks like this. Retatrutide runs for the length of the fat loss phase. Tesamorelin runs long enough to see a slow change, which means months, not weeks. They start at different times, they run for different reasons, and they finish at different points.
| Retatrutide | Tesamorelin | |
|---|---|---|
| Main job | Moves the scale through appetite and energy burn | Reduces deep visceral fat through a growth hormone pulse |
| Where it usually enters | First | Later, once weight is under control |
| How long it runs | For the length of the fat loss phase | Months, because visceral fat changes slowly |
| How fast results show | Weeks on the scale | Months, and best measured by waist or scan |
| What fades after stopping | Appetite control, and often the weight with it | The visceral fat reduction, over time |
Do you have to cycle off retatrutide and tesamorelin
This is where almost everyone gets it wrong, and it starts with the word itself. Most people borrow "cycle" from the anabolic steroid world, where you run something and then come off so your own hormone production can recover. That logic does not map cleanly onto these two compounds. Neither one is a compound where the main concern is your body building a tolerance and forcing a break.
So if the picture in your head is a planned on and off schedule like a steroid cycle, you can set it down. The question that actually matters is not "do I cycle off." It is "what happens when I stop," and the answer is different for each compound.
What happens when you stop retatrutide
Research on this drug class suggests that when you come off, appetite comes back, and a lot of the time the weight follows it if nothing else changed. Large trials on semaglutide and tirzepatide, the older compounds in the same family, showed a meaningful share of the lost weight returning within a year of stopping. Retatrutide does not have the same volume of off drug follow up data yet, but there is no strong reason to expect it to behave completely differently. The full pattern is broken down in why weight comes back after stopping retatrutide.
That makes stopping the hard part. For a lot of people, coming off is harder than staying on. The smart move is not planning a cycle. It is planning the exit before you need it, which means knowing what is going to hold the result when the compound is gone: protein intake, resistance training, and a slower taper rather than an abrupt stop.
What happens when you stop tesamorelin
Tesamorelin tells the same story for a different reason. Its benefit is tied to running it. In the extension phase of the approval trials, participants who were switched to placebo saw their visceral fat drift back toward where it started. There does not appear to be a permanent result you keep after you stop sending the signal. Stop the signal and, over time, the effect walks back.
When your body forces the pause
There is one more piece worth saying. Sometimes the body forces the pause. Retatrutide can push resting heart rate up, and some researchers have reported having to stop because their heart rate climbed too high. That is not a planned cycle. That is the body sending a signal, and a signal like that gets addressed right away, not pushed through. The man who treats a climbing heart rate as something to grit through is the man who ends up stopping anyway, later, with a bigger problem than the one he ignored.
Whether you stay on, stop, or adjust, the decision on retatrutide and tesamorelin rests on numbers you cannot feel, like fasting glucose, IGF-1, and how your resting heart rate and lipids are moving. This tool takes your age, goal, and symptoms and returns the exact panel to bring to your doctor, ranked by what matters first. Three minutes now versus a pause your body picks for you.
Show Me My PanelFree. No login. Takes about three minutes.
Retatrutide and tesamorelin dose: what the research used
A reference range is the span that shows up across the published research. It marks the boundaries of what was studied. It is not a number picked for any individual, and where someone lands inside it depends on body weight, tolerance, side effects, and goal. That is a bigger topic than one section can cover, and none of what follows is dosing guidance.
Retatrutide reference range and frequency
In clinical trials, retatrutide was studied from about 0.5 milligrams up to 12 milligrams once a week, usually starting low and stepping up over months. It is given weekly because it has a long half life, meaning it stays in the body for roughly six days before half of it has cleared.
Tesamorelin reference range and frequency
Tesamorelin was studied at about 1 to 2 milligrams per day, with the approved formulation at 2 milligrams daily and a newer formulation at a slightly lower amount. It is daily because it clears in well under an hour. Each injection produces its own growth hormone pulse rather than building up in the system. Food, especially carbohydrates, can raise insulin, and insulin tends to blunt a growth hormone pulse, which is why researchers often time it away from meals.
| Retatrutide | Tesamorelin | |
|---|---|---|
| Studied range | About 0.5 mg to 12 mg | About 1 mg to 2 mg |
| Frequency in research | Once weekly | Once daily |
| Why | Long half life, about six days | Short half life, under an hour |
| Timing note | Same day each week | Often away from food, since insulin can blunt the pulse |
The answer in three lines
Retatrutide runs for the fat loss phase and tesamorelin runs for months because the change it makes is slow, so the two are not on the same clock. Neither is a tolerance compound you have to cycle off, but stopping brings appetite back on one and fades the visceral fat change on the other. The real work is the exit, not the cycle, and the dose is a range, not a number.
Questions researchers ask next
If you still have a question this page did not settle, something like how long the overlap between retatrutide and tesamorelin should last, type it into the Research Engine and the first answer shows in full for free.
For research and educational purposes only. Not medical advice. Nothing on this page is a recommendation to use any compound.